[Commonly used antifungal agents in the treatment of systemic mycoses].
Berenguer Berenguer
J
J
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid.
D000666:Amphotericin B / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D001759:Blastomycosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003047:Coccidioidomycosis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D015725:Fluconazole / Q000627:therapeutic use; D005437:Flucytosine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000139:chemically induced; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D009181:Mycoses / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000139:chemically induced
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine; D007654:Ketoconazole